Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Pinnix, Chelsea C., Gunther, Jillian R., Dabaja, Bouthaina S., Strati, Paolo, Fang, Penny, Hawkins, Misha C., Adkins, Sherry, Westin, Jason, Ahmed, Sairah, Fayad, Luis, Lee, Hun Ju, Nair, Ranjit, Steiner, Raphael E., Iyer, Swaminathan P., Rodriguez, M. Alma, Wang, Michael, Flowers, Christopher, Neelapu, Sattva S., Nastoupil, Loretta J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362355/
https://ncbi.nlm.nih.gov/pubmed/32589728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001837
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados